NeuroPace (NPCE) Cash from Operations (QoQ) (2020 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | NeuroPace | 558.86 Mn | 504.88 Mn | 18.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,266.01% |
| Dec 31, 2025 | 126.46% |
| Sep 30, 2025 | 8.95% |
| Jun 30, 2025 | 72.00% |
| Mar 31, 2025 | -59.57% |
| Dec 31, 2024 | -165.24% |
| Sep 30, 2024 | 54.56% |
| Jun 30, 2024 | 48.19% |
| Mar 31, 2024 | -125.32% |
| Dec 31, 2023 | -47.83% |
| Sep 30, 2023 | 48.66% |
| Jun 30, 2023 | 54.61% |
| Mar 31, 2023 | -22.76% |
| Dec 31, 2022 | -13.69% |
| Sep 30, 2022 | 34.80% |
| Jun 30, 2022 | 6.45% |
| Mar 31, 2022 | -38.94% |
| Dec 31, 2021 | -84.27% |
| Sep 30, 2021 | 26.01% |
| Jun 30, 2021 | -1.31% |
| Mar 31, 2021 | 7.25% |
| Dec 31, 2020 | -17.65% |
| Sep 30, 2020 | -66.87% |
| Jun 30, 2020 | 49.85% |